Shilpa Medicare Subsidiary Enters CIRP Over ₹2.18 Crore Debt

Shilpa Medicare Limited’s wholly owned subsidiary FTF Pharma entered the corporate insolvency resolution process after the NCLT Ahmedabad admitted a ₹2.18 crore operational-debt petition on September 9, 2026. The listed company said the effect on its financial and operational activities was not currently ascertainable or quantifiable.

Why did FTF Pharma enter CIRP?

FTF Pharma entered CIRP after the Ahmedabad bench of the National Company Law Tribunal admitted an application under Section 9 of the Insolvency and Bankruptcy Code. The petition was filed by Immacule Lifesciences Private Limited over a claimed operational debt of ₹2,18,03,319.

The order was pronounced on September 9, 2026, in CP (IB) No. 346 (AHM) 2025. CIRP is the formal resolution process initiated for a corporate debtor under the IBC after an eligible insolvency application is admitted by the tribunal.

Shilpa Medicare disclosed the development on September 10. It stated that no violation by the listed company had been alleged or determined in connection with the matter.

What did the NCLT order require?

The NCLT order commenced CIRP against FTF Pharma and imposed a moratorium under Section 14 of the IBC. A moratorium restricts specified actions against the corporate debtor while the resolution process is in force.

The tribunal appointed Sunil Kumar Kedia as interim resolution professional, or IRP. The IRP is responsible for managing the corporate debtor during the initial stage of the process and carrying out duties prescribed under the insolvency framework.

Shilpa Medicare said it was evaluating its legal options with advisers. The company also said it would provide updates at an appropriate time as further developments emerge.

What are the key facts of the FTF Pharma insolvency case?

The case concerns FTF Pharma, a wholly owned subsidiary of Shilpa Medicare, and a claimed operational debt of ₹2.18 crore. The available disclosure identifies Immacule Lifesciences as the applicant and confirms that the CIRP began following the tribunal’s September 9 order.

The amount disclosed is the operational debt claimed in the insolvency petition. The source material does not state a final liability determination, recovery amount, resolution outcome, or settlement.

How could the CIRP affect Shilpa Medicare?

Shilpa Medicare said the impact of the CIRP on its own financial and operational activities was not presently ascertainable or quantifiable. That statement means the company has not disclosed a specific consolidated financial effect from the subsidiary’s insolvency process.

Because FTF Pharma is wholly owned, investors may monitor future disclosures for any effect on the subsidiary’s operations, assets, obligations, or the parent’s consolidated reporting. However, the current disclosure does not quantify any such impact.

The company also clarified that no direct violation by Shilpa Medicare had been alleged or determined. This distinguishes the insolvency proceeding against the subsidiary from an allegation of wrongdoing by the listed parent entity.

What is the broader context for Shilpa Medicare’s subsidiaries?

Shilpa Medicare has recently reported several regulatory and corporate developments across its group. Its Unit 4 at Jadcherla in Telangana received GMP certification from Austria’s AGES for Europe and global markets, according to the provided material.

The group has also disclosed product-related regulatory developments in India, including marketing authorisation permission for Adalimumab 40 mg/0.4 mL injection in a prefilled syringe through Shilpa Biologicals Private Limited. Separately, Shilpa Therapeutics Private Limited was approved for amalgamation with Shilpa Medicare by the NCLT Bengaluru bench, with an appointed date of April 1, 2025.

These developments relate to different entities and matters within the group. They do not change the disclosed fact that FTF Pharma is currently subject to CIRP following the Ahmedabad tribunal’s order.

Conclusion

The admission of the Section 9 petition places FTF Pharma under CIRP for a claimed operational debt of ₹2.18 crore, with a moratorium in place and Sunil Kumar Kedia appointed as IRP. Shilpa Medicare has not quantified the financial or operational effect on the listed parent and has said no violation by it has been alleged or determined.

Investors should watch for Shilpa Medicare’s next filing on its legal review, the subsidiary’s operational status, and any quantified effect on consolidated financials. The company has stated that it will provide updates when appropriate as the insolvency process develops.